Stemina Biomarker Discovery

Stemina Biomarker Discovery is a private U.S. biotechnology company focused on human in vitro toxicology testing and biomarker discovery. Its core commercial offerings include devTOX quickPredict for developmental toxicity and Cardio quickPredict for cardiotoxicity, which use human pluripotent stem cell-derived models and metabolomics to assess compound safety. The company also operates NeuroPointDX, a neurodevelopmental business unit developing biomarker-based tests for autism spectrum disorder and related neurological conditions. Stemina primarily serves pharmaceutical, chemical, consumer product, and regulatory stakeholders seeking alternatives to animal testing and more human-relevant safety screening. Overall, the company is best characterized as a platform-based biomarker and assay company with commercial services rather than a traditional therapeutic drug developer.